First patients to test new encapsulated cancer therapy
NCT ID NCT06694480
Summary
This is the first study in people to test the safety and side effects of a new cancer drug called FID-022. It will enroll 24 adults with advanced solid tumors that have no standard curative treatments available. The main goal is to find the highest dose patients can tolerate without severe side effects and to see how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USC/Norris Comprehensive Cancer Center and Hospital
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.